VivoSeq
Oncology

Medulloblastoma

73

Pipeline Programs↗

24

Active Trials↗

37

Companies Involved↗

Medulloblastoma is a moderately active landscape with 73 programs across 37 companies. The most active players are Sanofi, Merck & Co., Gema Biotech S.A.. 5 therapies are approved with 19 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

67/100

Pipeline Velocity

27/100

Mech. Concentration

8/100

Completion Rate

64/100

Attrition Rate

18/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Sanofi logo

Sanofi

2 programs

Phase 1Merck & Co. logo

Merck & Co.

1 program

Phase 1G

Gema Biotech S.A.

1 program

Phase 1Bristol-Myers Squibb logo

Bristol-Myers Squibb

2 programs

Phase 2Pfizer logo

Pfizer

2 programs

Phase 2Novartis logo

Novartis

1 program

Phase 2

Pipeline

Programs by Phase

Analysis

Modality Breakdown

84%

Small molecule

65 of 77 classified programs — the dominant modality here.

16%ALL OTHERSMonoclonal antibody45%Vaccine45%Protein / enzyme34%Cell therapy11%

Small molecule leads; the ring shows all 77 classified programs, each share of the total. Modality classified for 100% of 82 pipeline programs.

Analysis

Trial Status

55

clinical trials

Completed18 · 33%
Recruiting11 · 20%
Terminated9 · 16%
Active, not recruiting8 · 15%
Not yet recruiting5 · 9%
Unknown status3 · 5%
Other1 · 2%

Clinical Trials

Trial Activity

55 trials

DFMO as Maintenance Therapy for Molecular High/Very High Risk and Relapsed Medulloblastoma
Recruiting·—·Phase 2·NCT04696029·118 enrolled
Molecular and Clinical Risk-Directed Therapy for Infants and Young Children With Newly Diagnosed Medulloblastoma
Recruiting·SSt. Jude Children's Research Hospital·Phase 2·NCT05535166·130 enrolled
PEP-CMV Vaccine Targeting CMV Antigen to Treat Newly Diagnosed Pediatric HGG and DIPG and Recurrent Medulloblastoma
Recruiting·NNationwide Children's Hospital·Phase 2·NCT05096481·120 enrolled
Antiangiogenic Therapy for Children With Recurrent Medulloblastoma, Ependymoma, ATRT and Rare CNS Tumors
Recruiting·MMedical University of Vienna·Phase 2·NCT01356290·232 enrolled
GPC2-CAR T Cell Therapy for Relapsed or Refractory Medulloblastoma in Children and Young Adults
Recruiting·SStanford University·Phase 1·NCT07087002·18 enrolled
A Study of Treatment for Medulloblastoma Using Sodium Thiosulfate to Reduce Hearing Loss
Recruiting·Children's Oncology Group·Phase 3·NCT05382338·225 enrolled
Novel Molecular Targets and Innovative Therapeutic Perspective in Medulloblastoma
Recruiting·FFondazione Policlinico Universitario Agostino Gemelli IRCCS·Phase 1·NCT06959979·60 enrolled
Apatinib Combined with Temozolomide and Etoposide Capsules in the Treatment of Recurrent Medulloblastoma in Children
Recruiting·—·Phase 2·NCT04501718·44 enrolled
Evaluation of Digoxin for Relapsed Non-WNT, Non-SHH Medulloblastoma
Recruiting·HH. Lee Moffitt Cancer Center and Research Institute·Phase 2·NCT06701812·23 enrolled
CSIMEMPHIS: Long-term Follow-up of Medulloblastoma Survivors That Received Craniospinal Irradiation
Recruiting·SSt. Jude Children's Research Hospital·N/A·NCT07085325·184 enrolled
Parental Distress as a Predictor of Treatment Adherence in Pediatric Recurrent Medulloblastoma: A Prospective Longitudinal Cohort Study
Recruiting·WWest China Hospital·N/A·NCT07660458·450 enrolled
A Clinical and Molecular Risk-Directed Therapy for Newly Diagnosed Medulloblastoma
Active, not recruiting·SSt. Jude Children's Research Hospital·Phase 2·NCT01878617·660 enrolled
Brain Tumor-Specific Immune Cells (IL13Ralpha2-CAR T Cells) for the Treatment of Leptomeningeal Glioblastoma, Ependymoma, or Medulloblastoma
Active, not recruiting·—·Phase 1·NCT04661384·10 enrolled
Chemotherapy and Radiation Therapy in Treating Young Patients With Newly Diagnosed, Previously Untreated, High-Risk Medulloblastoma/PNET
Active, not recruiting·Children's Oncology Group·Phase 3·NCT00392327·379 enrolled
131I-Omburtamab, in Recurrent Medulloblastoma and Ependymoma
Active, not recruiting·PPediatric Brain Tumor Consortium·Phase 2·NCT04743661·62 enrolled
Page 1 of 4

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)